

Nectar Lifesciences Ltd.



Ref: NLL\CS\2014- 581

June 11, 2014

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI - 400 051.
2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI - 400 001.

Sub. Investors Press Release

Dear Sirs,

Please find attached herewith an Investor Press release that "NecLife gets European cGMP Approval for its Orals & Injectables Cephalosporins FDF Facility."

This is for your information and necessary dissemination to investors.

Thanking you,

Yours faithfully,

For Nectar Lifesciences Limited

(Dinesh Dua)

CEO & Director



NECTAR LIFESCIENCES LIMITED

Sco 38-39, Sector 9 D, Madhya Marg, Chandigarh 160009, U.T., India

For immediate release

NecLife gets European cGMP Approval for its Orals & Injectables Cephalosporins FDF Facility

Chandigarh, 11 June, 2014

Nectar Lifesciences Limited (NecLife or NLL), the fast-growing manufacturer of generic pharmaceutical active pharmaceutical ingredients (APIs) and formulation products has touched a significant milestone by receiving 2nd European cGMP ("Current Good Manufacturing Practices") approval for its Cephalosporin Finished Dosage Forms (FDF) manufacturing facility in Baddi, Himachal Pradesh.

NecLife has received 2nd European cGMP compliance certification for both Oral & Injectables Cephalosporins followed by the successful inspection by the Portugal Authority - National Authority of Medicines and Health Products, INFARMED in July 2013. The INFARMED Certificate is accepted by all EU Health Authorities and by authorities of several other countries.

NecLife's FDF facility, Unit-VI, has received this approval for all the Cephalosporin steriles and Non-sterile products which includes tablets, capsule, powder for oral suspension and powder for injections. This approval is a testimony to the high standards of quality and compliance practices put in place by the company. This approval will facilitate exports to the lucrative generic drug markets of Europe and this certification opens up lot of opportunities for Contract Manufacturing for NecLife for European customers. In addition to EU approval NLL is eagerly awaiting USFDA approval in writing anytime for its FDF & API facility inspections by USFDA between 12th Jan – 24th Jan'14.

Till date, NecLife has filed 36 Drug Master Files (DMFs) and 12 Abbreviated New Drug Applications (ANDAs) with 3 more ANDA filings in next 10 days, taking total ANDA filings in US to 15. NecLife has very ambitious plan of filing multiple DMFs, ANDAs/ EU dossiers in US and EU markets in year 2014-15. These filings by NecLife will result in robust topline as well as bottomline for the company from year 2015 onwards in view of gestation period for regulatory approvals which take significant time in view of the current pendency.

About Nectar Lifesciences Limited (NecLife)

Established in 1995, NecLife (BSE code: 532649, NSE Id: NECLIFE, ISIN Id: INE023H01027) is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin and Carbapenem active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The Company is growing presence in empty hard gelatine capsules (EHGCs) and menthol products. NecLife is one of the largest manufacturers of cephalosporin range of products and has an established brand presence in 20 states across India and 50 countries across five continents. NecLife has a global leadership position in 3 oral molecules and global No. 2 position in 2 sterile molecules. The Company has 11 manufacturing facilities – eight in Derabassi, Punjab (API and menthol units), two in Baddi, Himachal Pradesh (FDF and EHGC plants) and one in Jammu (menthol plant). NecLife's products include Oral and sterile cephalosporin, Carbapenem and other APIs, FDFs, Empty hard gelatin capsules and Menthol and allied products.

Additional information on NecLife is available on the Company website www.neclife.com.

Investor contacts

Dinesh Dua

Nectar Lifesciences Limited

Phone: +91 172 304 7766

Fax: +91 172 507 9049

Email: dinesh.dua@neclife.com

Note: This document contains 'forward-looking' statements at places. The Company has operations across several segments of business and remains subject to undetermined contingencies and risks. Nectar Lifesciences would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.